Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Keyur PatelStephen A HarrisonMagdy ElkhashabJames F TrotterRobert HerringSergio E RojterZeid KayaliVincent Wai-Sun WongSusan GreenbloomSaumya JayakumarMitchell L ShiffmanBradley FreilichEric J LawitzEdward J GaneEliza HartingJun XuAndrew N BillinChuhan ChungC Stephen DjedjosG Mani SubramanianRobert P MyersMichael S MiddletonMary RinellaMazen NoureddinPublished in: Hepatology (Baltimore, Md.) (2021)
Cilofexor for 24 weeks was well-tolerated and provided significant reductions in hepatic steatosis, liver biochemistry, and serum bile acids in patients with NASH. ClinicalTrials.gov No. NCT02854605.